Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in…

Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)

Go here to see the original:
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in...

Related Posts